News/ News/ R&D Two biotechs target dry eye disease after Novartis’ Xiidra problems Richard Staines Azura, dry-eye disease, Novartis, ophthalmology, PharmaMar, R&D 0 Comment The pipeline for dry eye disease drugs is beginning to heat up, with two biotechs announcing key developments, Share X Two biotechs target dry eye disease after Novartis’ Xiidra problems https://pharmaphorum.com/news/two-biotechs/
Azura, dry-eye disease, Novartis, ophthalmology, PharmaMar, R&D
0 Comment
